Drugs /

cetrelimab

Back to Drugs List

Overview

NCI Definition [1]:
A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 protein (PD-1, PCDC-1), with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cetrelimab binds to PD-1, and inhibits the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.

Clinical Trials

View Clinical Trials for cetrelimab

Cetrelimab has been investigated in 9 clinical trials, of which 9 are open and 0 are closed. Of the trials investigating cetrelimab, 1 is phase 1 (1 open), 3 are phase 1/phase 2 (3 open), 4 are phase 2 (4 open), and 1 is phase 3 (1 open).

Deficient DNA Mismatch Repair (dMMR), MLH1 Deficient Expression, and MSH2 Deficient Expression are the most frequent biomarker inclusion criteria for cetrelimab clinical trials.

Prostate adenocarcinoma, bladder carcinoma, and bladder urothelial carcinoma in situ are the most common diseases being investigated in cetrelimab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Cetrelimab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating cetrelimab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
cetrelimab, jnj-63723283, jnj63723283, who 10757, jnj 63723283
Drug Target(s) [2]:
PDCD1
NCIT ID [1]:
C129448

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.